Announcement

Collapse
No announcement yet.

Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
Working...
X